Baader Bank Aktiengesellschaft Boosts Position in Danaher Corporation $DHR

Key Points

• Baader Bank Aktiengesellschaft increased its stake in Danaher Corporation by 22.1%, owning 9,606 shares valued at approximately $1,740,000 after acquiring additional shares in Q2.
• Danaher recently reported earnings of $1.80 EPS, surpassing estimates, and recorded a revenue of $5.94 billion for the quarter, a 3.4% increase year-over-year.
• The company announced a quarterly dividend of $0.32 per share, with the ex-dividend date set for September 26th, providing an annual yield of 0.7%.

Baader Bank Aktiengesellschaft boosted its position in Danaher Corporation (NYSE:DHR - Free Report) by 22.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,606 shares of the conglomerate's stock after purchasing an additional 1,741 shares during the quarter. Baader Bank Aktiengesellschaft's holdings in Danaher were worth $1,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently made changes to their positions in the company. MGO One Seven LLC raised its position in shares of Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after buying an additional 20,813 shares in the last quarter. UniSuper Management Pty Ltd raised its position in shares of Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock valued at $34,954,000 after buying an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in shares of Danaher during the 1st quarter valued at $539,000. Horizon Financial Services LLC raised its position in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after buying an additional 8,160 shares in the last quarter. Finally, Focus Partners Wealth raised its position in shares of Danaher by 10.7% during the 1st quarter. Focus Partners Wealth now owns 196,682 shares of the conglomerate's stock valued at $40,328,000 after buying an additional 19,086 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company's stock.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research report on Tuesday, September 2nd. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Guggenheim reiterated a "buy" rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $245.91.

Danaher Stock Performance

Shares of DHR traded down $2.99 during mid-day trading on Monday, hitting $190.30. 2,949,617 shares of the company traded hands, compared to its average volume of 3,371,563. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock has a 50-day moving average price of $200.02 and a two-hundred day moving average price of $198.03. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The stock has a market cap of $136.26 billion, a price-to-earnings ratio of 40.49, a P/E/G ratio of 2.70 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.